PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩215 per share · Prices as of the 2026-10-02 close
JW Holdings has shown steady improvement in operating margin and financial structure, while its core subsidiary JW Pharmaceutical's Phase 3 success for a gout drug candidate has emerged as a key variable for the holding company's value.
2025 consolidated operating margin reached 17.3%, up steadily from 11.9% in 2022
Debt ratio fell sharply from 247.3% in 2022 to 107.1% in 2025, stabilizing the balance sheet
Owner net income over the latest four quarters (2025Q3-2026Q2) reached KRW 84.5bn, already exceeding full-year 2025
JW Pharmaceutical confirmed statistical superiority of gout candidate Epaminurad over standard therapy in a multinational Phase 3 trial (August 2026)
JW Group has expanded cash dividends across its four listed units and moved year-end dividend disclosure up to December as part of shareholder return policy
JW Holdings is a pure holding company established in 2007 through the spin-off of the investment division from JW Pharmaceutical, with JW Pharmaceutical, JW Life Science, and JW Shinyak as its main subsidiaries.
JW Holdings itself generates revenue mainly through dividend income from subsidiary equity stakes, brand royalty fees, and affiliate management service fees, while it also directly runs overseas export operations for raw materials, finished pharmaceuticals, and medical devices produced by subsidiaries and sub-subsidiaries.
By revenue composition, the holding business (dividends, brand fees, management fees) accounts for the largest share at 43.1%, followed by penem-class drugs at 21.5%, other pharmaceuticals at 15.5%, IV fluid products at 14.8%, itraconazole-related products at 3.0%, and medical devices at 2.1%.
Core subsidiary JW Pharmaceutical leads the domestic therapeutic drug market with a strong original drug pipeline and pursues innovative new drug development through its global R&D network.
JW Life Science is a global specialist in IV fluid production, having built automated systems spanning molding, filling, sterilization, and packaging of Non-PVC IV containers.
JW Shinyak holds a competitive edge in the dermatology, urology, and otolaryngology clinic markets and is expanding into cell therapy through its subsidiary JW CreaGene. In medical devices, JW Medical supplies advanced imaging diagnostic equipment including 3D digital mammography, MRI, CT, and endoscopy systems.
In terms of competitive landscape, the group's core operating company competes with major domestic players such as Yuhan Corporation, GC Biopharma, and Daewoong Pharmaceutical amid the industry-wide push into new drug R&D.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩228.4B | ₩41B | 18.0% |
| 2025Q3 | ₩244.1B | ₩47.2B | 19.3% |
| 2025Q4 | ₩257.6B | ₩38B | 14.7% |
| 2026Q1 | ₩243.2B | ₩51.5B | 21.2% |
| 2026Q2 | ₩266.5B | ₩53.8B | 20.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩864.5B | ₩103.3B | ₩22.2B | 11.9% | 20.7% | 247.3% |
| 2023 | ₩928.1B | ₩144.9B | ₩19B | 15.6% | 15.3% | 237.3% |
| 2024 | ₩887.7B | ₩146.5B | ₩62.6B | 16.5% | 27.3% | 139.9% |
| 2025 | ₩969.6B | ₩167.9B | ₩58.5B | 17.3% | 21.9% | 107.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
JW Holdings' 2025 consolidated revenue reached KRW 969.6bn, up from KRW 887.7bn in 2024, while operating profit rose to KRW 167.9bn from KRW 146.5bn, extending a four-year improvement in operating margin from 11.9% in 2022 to 15.6% in 2023, 16.5% in 2024, and 17.3% in 2025.
Owner net income, however, edged down to KRW 58.5bn in 2025 from KRW 62.6bn in 2024, a divergence from operating profit growth that appears linked to structural factors such as minority interest allocation at subsidiaries.
Owner net income jumped more than threefold from KRW 19.0bn in 2023 to KRW 62.6bn in 2024 and has since held in the high-KRW 50bn range through 2025, marking a step-up in the company's earnings scale.
On a quarterly basis, owner net income was unusually low at about KRW 4.0bn in 2025Q2 before rising to KRW 21.6bn in Q3, KRW 22.8bn in Q4, KRW 20.7bn in 2026Q1, and KRW 19.4bn in 2026Q2, settling into a roughly KRW 20bn-per-quarter pattern.
Owner net income summed over the latest four quarters (2025Q3-2026Q2) reached KRW 84.5bn, already exceeding the full-year 2025 figure of KRW 58.5bn, pointing to continued earnings improvement.
Operating profit also trended broadly upward, at KRW 47.2bn in 2025Q3, KRW 38.0bn in Q4, KRW 51.5bn in 2026Q1, and KRW 53.8bn in 2026Q2.
On the balance sheet, the debt ratio fell sharply from 247.3% in 2022 and 237.3% in 2023 to 139.9% in 2024 and 107.1% in 2025, while operating cash flow rose to KRW 163.7bn in 2025 from KRW 97.9bn in 2024, indicating improved cash generation. Owner equity likewise expanded from KRW 107.0bn in 2022 to KRW 267.0bn in 2025, broadening the capital base.
Korea's pharmaceutical industry is shaped by both rising chronic disease patient numbers amid population aging and government drug pricing management, giving companies with original and improved new drugs a more stable prescription base.
According to FnGuide, the global pharmaceutical market is expected to reach USD 1.9 trillion by 2027, with growth in chronic diseases cited as a supporting factor for continued industry expansion.
In the ethical drug (ETC) market, prescription growth for original products continues in areas such as dyslipidemia, anemia, and benign prostatic hyperplasia treatments, while in the IV fluid market, competitiveness hinges on high-value product lineups built on Non-PVC container technology.
Among domestic pharmaceutical companies, leading players including Yuhan Corporation, GC Biopharma, Hanmi Pharmaceutical, Chong Kun Dang, and Daewoong Pharmaceutical are visibly increasing R&D investment in new drug development, and the JW Group has similarly expanded pipeline investment in areas such as gout treatments and oncology candidates.
In the nutritional IV fluid segment, competition is gradually intensifying as rival companies expand their lineups.
Within the holding company sector, improvements at operating subsidiaries translate directly into higher dividend income for the parent, making subsidiaries' original drug prescription growth and pipeline outcomes the key variable for holding company earnings.
In August 2026, JW Pharmaceutical announced that the 6mg dose of its gout treatment candidate Epaminurad (code name URC102) demonstrated statistical superiority over 40mg febuxostat, the standard therapy, in a multinational Phase 3 trial.
Conducted across 52 institutions in five Asian countries—Korea, Taiwan, Thailand, Malaysia, and Singapore—the trial enrolled 612 gout patients and showed the Epaminurad 6mg group achieved a serum uric acid level below 6mg/dL in 50.0% of cases, versus 38.3% for the control group, with no drug-related safety issues reported.
The candidate has also been selected for the Ministry of Food and Drug Safety's pilot program for innovative new drug approval and review procedures, making the pace of subsequent domestic approval a point to watch.
According to FnGuide, in addition to the global Phase 3 progress for URC102, the JW Group is advancing innovative drug development on multiple fronts, including Phase 1 approval for STAT3-targeted oncology candidate JW2286 and selection of a prostate cancer treatment for a national new drug development program.
Existing original prescription drugs—the Livalo family, Hemlibra, Ferinject, and Trupas—have continued to post double-digit revenue growth on a standalone basis at subsidiary JW Pharmaceutical, providing funding support for pipeline investment.
The group has expanded cash dividends across its four listed entities (JW Holdings, JW Pharmaceutical, JW Life Science, and JW Shinyak) and moved the year-end dividend disclosure timing up from February of the following year to December of the current year to improve shareholder predictability.
JW Pharmaceutical has separately decided on share buybacks, reflecting a broader push to strengthen shareholder returns.
JW Holdings' share price trades at a level not far from its book value per share, meaning the stock shows neither a pronounced premium nor discount relative to net assets.
Given that owner net income over the latest four quarters, even annualized, has already surpassed the full-year 2025 figure, the relationship between this pace of earnings improvement and the market's valuation response is worth monitoring.
On the dividend side, a notable feature is that the JW Group has expanded cash dividends across its listed affiliates and moved dividend disclosure timing earlier, strengthening its shareholder return policy.
Given the holding company structure, JW Holdings' value ultimately hinges on the operating performance and equity-method gains of subsidiaries such as JW Pharmaceutical, leaving subsidiary earnings and new drug pipeline outcomes as the key variables for future valuation.
The marked decline in the debt ratio over the past four years is a notable change from a financial soundness perspective.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
Operating margin rose steadily from 11.9% in 2022 to 17.3% in 2025, while the debt ratio fell sharply from 247.3% to 107.1% over the same period. Operating cash flow also jumped to KRW 163.7bn in 2025 from KRW 97.9bn a year earlier, indicating improved cash generation.
Owner net income summed over the latest four quarters (KRW 84.5bn) has already exceeded the full-year 2025 figure, showing continued earnings momentum.
In August 2026, JW Pharmaceutical announced that its gout candidate Epaminurad demonstrated statistical superiority over standard therapy in a multinational Phase 3 trial.
The drug outperformed the control group by 12.0 percentage points in achieving target serum uric acid levels, with no notable safety issues reported.
The candidate has also been selected for the MFDS pilot program for innovative drug approval and review, drawing attention to the pace of subsequent regulatory procedures.
The JW Group has expanded cash dividends across its four listed entities, with JW Holdings' cash dividend confirmed at around KRW 46bn.
It also moved the year-end dividend disclosure timing up to December to improve shareholder predictability, while JW Pharmaceutical has separately decided on share buybacks, diversifying its shareholder return measures.
Owner net income in 2025Q2 was unusually low at around KRW 4.0bn compared to roughly KRW 20bn in other quarters, showing significant quarter-to-quarter variability.
This is presumed to stem from structural factors specific to holding companies, such as profit allocation and minority interest adjustments at subsidiaries, making it difficult to judge trends from a single quarter's results.
Korea's pharmaceutical industry is exposed to policy risks such as government drug price cuts and rebate regulation, while competition in the nutritional IV fluid market is gradually intensifying as rivals expand their lineups.
A portfolio centered on original drugs may also face long-term margin pressure from patent expirations and generic entry.
Even though Epaminurad confirmed statistical superiority in Phase 3, formal approval by regulators at home and abroad and eventual commercialization will require additional time and cost. Follow-on pipeline candidates such as STAT3-targeted oncology drug JW2286 remain at the Phase 1 stage, with success still uncertain.
Government policy changes such as drug price re-evaluation, rebate regulation, and essential medicine designation could directly affect subsidiaries' prescription drug sales. If health insurance fiscal management continues to tighten, reimbursement conditions or pricing for new drugs could fall short of expectations.
While Epaminurad confirmed statistical superiority in Phase 3, delays or requests for additional data remain possible at each subsequent stage of approval filing, review, and commercialization. Earlier-stage pipeline candidates such as JW2286 remain exposed to clinical trial failure risk.
JW Holdings' earnings depend on the equity-method income and dividend policies of its subsidiaries, so any deterioration in subsidiary performance or changes to dividend policy could affect the parent's results. The way minority interests are allocated can also amplify quarter-to-quarter volatility in owner net income.
Check whether JW Holdings and JW Pharmaceutical disclose preliminary 2026Q3 results and whether sales momentum continues for key products such as the Livalo family and Ferinject.
Under the JW Group's advanced year-end dividend disclosure schedule, this is the point to check the announced 2026 cash dividend amounts for JW Holdings and its three other listed affiliates.
Monitor the progress of domestic and overseas new drug approval (NDA) filings for Epaminurad following its Phase 3 statistical superiority result, as well as progress under the MFDS innovative drug approval pilot program.
Track the timing of Phase 1 data disclosure for STAT3-targeted oncology candidate JW2286 and follow-up progress on the prostate cancer treatment selected under the national new drug development program.
JW Holdings is a pure holding company with JW Pharmaceutical, JW Life Science, and JW Shinyak as subsidiaries, generating its own revenue from subsidiary dividends, brand royalty fees, management fees, and overseas trading of raw materials, finished pharmaceuticals, and medical devices.
Consolidated operating margin improved steadily from 11.9% in 2022 to 17.3% in 2025, while the debt ratio fell sharply from 247.3% to 107.1% over the same period, reflecting a stabilizing financial structure.
Owner net income surged from KRW 19.0bn in 2023 to KRW 62.6bn in 2024, settled at KRW 58.5bn in 2025, and reached KRW 84.5bn over the latest four quarters—showing quarter-to-quarter variability but an overall step-up in earnings scale.
Core subsidiary JW Pharmaceutical delivered visible pipeline progress, confirming statistical superiority of gout candidate Epaminurad over standard therapy in Phase 3, while existing original drugs such as the Livalo family and Ferinject continued to post stable growth.
On the other hand, factors to weigh include quarter-to-quarter net income volatility inherent to the holding company structure, drug pricing regulation and intensifying competition, and the time and cost still required before new drugs reach commercialization.
Overall, this report does not offer an investment opinion or target price, and is intended solely to provide the facts and metrics summarized above so that readers can form their own judgment.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.